Companies expanding their biologics portfolios represent a $5 billion market opportunity by 2026, according to a Sept. 9 news release. In recent months companies including Vericel, LifeNet Health and SurGenTec made advances with their spine and orthopedic biologic portfolios, earning FDA nods.
Major players mentioned in the report include Arthrex, Alphatec and Zimmer Biomet.
The spine device market is also expected to grow due to factors such as rising investments in 3D printed technology, demand for motion preserving devices and adoption of minimally invasive procedures, according to the report.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
